Document Detail

Expression of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ) in Human Non-small Cell Lung Carcinoma: Correlation with Clinicopathological Parameters, Proliferation and Apoptosis Related Molecules and Patients' Survival.
MedLine Citation:
PMID:  22426809     Owner:  NLM     Status:  Publisher    
Peroxisome proliferator-activated receptor-γ (PPAR-γ) has currently been considered as molecular target for the treatment of human metabolic disorders. PPAR-γ has also been implicated in the pathogenesis and progression of several types of cancer, being associated with cell differentiation, growth and apoptosis. The present study aimed to evaluate the clinical significance of PPAR-γ expression in non-small cell lung carcinoma (NSCLC). PPAR-γ protein expression was assessed immunohistochemically in tumoral samples of 67 NSCLC patients and was statistically analyzed in relation to clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival. Positive PPAR-γ expression was prominent in 30 (45 %) out of 67 NSCLC cases. PPAR-γ positivity was more frequently observed in squamous cell lung carcinoma cases compared to lung adenocarcinoma ones (p = 0.048). PPAR-γ positivity was significantly associated with bcl-2 positivity (p = 0.016) and borderline with c-myc positivity (p = 0.052), whereas non associations with grade of differentiation, TNM stage, Ki-67, p53, bax proteins' expression and patients' survival were noted. In the subgroup of squamous cell lung carcinoma cases, PPAR-γ positivity was significantly associated with tumor size (p = 0.038), while in lung adenocarcinoma ones with histopathological grade of differentiation (p = 0.026). The present study supported evidence for possible participation of PPAR-γ in the biological mechanisms underlying the carcinogenic evolution of the lung. Although the survival prediction using PPAR-γ expression as a marker seems uncertain, the observed correlation with apoptosis related proteins reinforces the potential utility of PPAR-γ ligands as cell cycle modulators in future therapeutic approaches in lung cancer.
Costantinos Giaginis; Ekaterini Politi; Paraskevi Alexandrou; John Sfiniadakis; Gregory Kouraklis; Stamatios Theocharis
Related Documents :
23457619 - Madd knock-down enhances doxorubicin and trail induced apoptosis in breast cancer cells.
23072969 - Serum glutamate levels correlate with gleason score and glutamate blockade decreases pr...
22783529 - Recipient vessel selection in immediate breast reconstruction with free abdominal tissu...
23170139 - Effects of sirna-mediated knockdown of jumonji domain containing 2a on proliferation, m...
23158079 - Study of the betulin enriched birch bark extracts effects on human carcinoma cells and ...
22397589 - Health care cost attributable to recently diagnosed breast cancer in a privately insure...
7704039 - Association between a cytochrome p450 cypia1 genotype and incidence of lung cancer.
20807849 - Can preoperative axillary us help exclude n2 and n3 metastatic breast cancer?
18709409 - Magnetic resonance images and linear measurements in the surgical treatment of breast a...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-18
Journal Detail:
Title:  Pathology oncology research : POR     Volume:  -     ISSN:  1532-2807     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9706087     Medline TA:  Pathol Oncol Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Forensic Medicine and Toxicology, Medical School, University of Athens, 75 Mikras Asias Street, Athens, 11527, Greece,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human...
Next Document:  Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer.